Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
The final session culminated in a discussion chaired by Professor John McMurray, which centred on three questions based on the key themes and topics presented during the two day meeting.
Are renin-angiotensin system modulators effective in reducing cardiovascular mortality and morbidity solely due to their effect on blood pressure, or can their efficacy be attributed to additional benefits?
There was a general agreement that, although the primary goal remains effective blood pressure lowering, there must be other additional mechanisms responsible for the impressive efficacy of renin-angiotensin system modulators. Dr Meredith pointed out that STOP-Hypertension-2 showed a selective benefit associated with angiotensin converting enzyme (ACE) inhibitors in terms of incidence of myocardial infarction and frequency of heart failure.1 In addition, a review of data from the Glasgow blood pressure clinic reveals a benefit associated with ACE inhibitors which is independent of blood pressure lowering. However, if blood pressure is lowered sufficiently, the difference between treatments becomes less apparent.
Professor Swedberg acknowledged that ACE inhibitors and β blockers are doing more than was anticipated when they were …
Chair: John McMurray
Panel: Jim Shepherd Richard Hobbs Karl Swedberg Peter Meredith